A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
TO THE EDITOR: Since 2000, several small randomized controlled trials have demonstrated that ketamine has potent and rapid-acting antidepressant effects in patients with treatment-resistant depression (1). Despite a lack of longterm data or Food and Drug Administration indication, many community providers and academic centers have begun offering ketamine treatment to patients with major depressive disorder and with other psychiatric disorders, determining the existing evidence justifies use for some individuals. Thepractice patterns of suchprovidershavenot been studied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“An overall total of 33,240 (e.g.23,420 zolpidem; 9,283 zopiclone; and 537 zaleplon) misuse/abuse/dependence and withdrawal-related ADRs, corresponding to some 6,246 unique patients, were identified.”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [33]
Experimental — accuracy not yet measuredIn the citing paper
“Out of these three molecules, zolpidem and zopiclone presented with the same dependence risk, but zolpidem was the most frequently associated with withdrawal issues.Zaleplon was the least reported for these ADRs (see Table 1).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Morgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02761.x · Cited by 373
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
A REVIEW OF KETAMINE ABUSE AND DIVERSION: Review: Ketamine
Sassano-Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016) · Depression and Anxiety · doi:10.1002/da.22536 · Cited by 204
Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders
Sanacora, G., Heimer, H., Hartman, D., Mathew, S. J., Frye, M., Nemeroff, C. B., & Beale, R. R. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.193 · Cited by 37
Self-citation
Cited by
Items 101–140 of 140
Ketamine in the Real World: Where Do We Go From Here?
Wilkinson, S. T. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22com14648 · Cited by 2
Self-citationSearching for Treatments for Cocaine Use Disorder: The Quest Continues
Brady, K. T. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19080890 · Cited by 2
How Ketamine Became an AntidepressantPreprint
Joralemon, V. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5519058 · Cited by 2
Gregoire, N. (2025) · cIRcle (University of British Columbia) · doi:10.14288/1.0448342 · Cited by 2
Sampy, S., & Sampy, R. (2025) · University of Ottawa Journal of Medicine · doi:10.18192/uojm.v15i2.7456 · Cited by 1
Appley, M., Gray, J. R., Abdulrahim, D., & Bowden‐Jones, O. (2026) · Addiction Science & Clinical Practice · doi:10.1186/s13722-026-00645-7 · Cited by 1
“Recently, there has also been significant interest in ketamine as a treatment for mental health conditions [2, 3].”
Kosted, R., Waddell, A., Adolph, K., & Fonzo, G. A. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121350 · Cited by 1
Abukahok, N., Lawrence, S., Adhikari, S., Wilkinson, S. T., & Palamar, J. J. (2026) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70095 · Cited by 1
“A survey of ketamine-prescribing clinicians conducted in 2020–21 found that 68% of such clinics reported having a physician on their team [22], while a 2023 study found that less than 30% of ketamine clinics are run by a psychiatric physician [37].”
Self-citationAntidepressants: Pharmacology and Biochemistry
Efinger, V., Müller, W. E., & Friedland, K. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_26-1 · Cited by 1
Antidepressants: Pharmacology and Biochemistry
Efinger, V., Müller, W. E., & Friedland, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_26 · Cited by 1
An, Y., Park, S.-Y., & Kang, U. G. (2022) · 신경정신의학 · doi:10.4306/jknpa.2022.61.4.243 · Cited by 1
President’s message: the dangers of ketamine clinic proliferation
Mangiacarne, D. (2025) · Journal of Addictive Diseases · doi:10.1080/10550887.2025.2536889 · Cited by 1
The Rise of Ketamine in Clinical Practice
Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180314-02
Self-citationKetamin in der Behandlung depressiver Episoden
Deuschle, M., & Gilles, M. (2018) · Nervenheilkunde · doi:10.1055/s-0038-1670570
Cook, I. A. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180036
Ketamine for Psychiatric Disorders
McShane, R. H. (2019) · Cambridge University Press eBooks · doi:10.1017/9781911623175.017
Ketamine, Esketamine, and A New Generation of Antidepressants
Wilkinson, S. T., & Kitay, B. M. (2020) · Psychiatric Annals · doi:10.3928/00485713-20200113-02
Self-citationKetamina eta esketaminaren erabilera depresioerresistentea tratatzeko: etorkizunerako erronkak
Elexpe, A., Bruzos-Cidón, C., Cabrera, M., Barreda‐Gómez, G., & Torrecilla, M. (2020) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.21862
Use of Medications in Suicide Prevention
Moutier, C. Y., Pisani, A. R., & Stahl, S. M. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108564618.009
Brietzke, E. M., Zarate, C. A., & Vázquez, G. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00008-3
Geller, J. A., Keith, K. M., & Mischel, N. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001697
Risk Evaluation and Mitigation Strategy programs: How they can be improved
Cooke, C. E. (2023) · Current Psychiatry · doi:10.12788/cp.0375
Chapter 22. Ketamine and Other Investigational Agents
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379620.lg22
Effects of Ketamine and Esketamine on Cognitive Functions in Treatment-Resistant Depression
Mutlu, M., Öven, Ç., Kurt, B. S., & SUNAY, E. (2025) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1524106
Ketamine’s Evolving Role in Addressing Treatment Resistant Depression
Rosenhagen, M. C., & Forte, A. M. (2024) · Journal of Medical - Clinical Research & Reviews · doi:10.33425/2639-944x.1405
Chrenek, C., & Swainson, J. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_12
Substâncias psicadélicas como "novas" estratégias terapêuticas na psiquiatria
Lopes, T. G. G. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/jaws-ym77
Meine, L. E. (2021) · Gutenberg Open Science · doi:10.25358/openscience-6468
Clinician Education: Optimizing Music Choices for Ketamine-Assisted Psychotherapy
Chenette, C. I., & Chenette, C. I. (2024) · UA Campus Repository (The University of Arizona)
Predictors of the Antidepressant Effects of Ketamine and Psychedelic Substances
Syed, O. A. (2025) · TSpace (University of Toronto)
Chang, L. (2020) · Institutional Repositories DataBase (IRDB) · doi:10.20776/109391
Buchanan, J., Reynante, B. M., Dinh, M. T., & Zamaria, J. A. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2685515
Torii, K., & Jinno, M. (2026) · Journal of Patient Safety and Risk Management · doi:10.1177/25160435261466115
Hardy, M. S., Li, S. W., & Wilkinson, S. T. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20260001
Self-citationKetamine Therapy in Psychiatry: A Comprehensive Review
Khan, A., *, S., Nair, S. K., & Joseph, D. G. (2025) · Journal of Psychiatric Nursing · doi:10.21088/jpn.2277.9035.14125.5
Ketamine Therapy in Psychiatry: A Comprehensive Review
Khan, A., *, S., Nair, S. K., & Joseph, D. G. (2025) · Journal of Psychiatric Nursing · doi:10.21088/jpn.2277.9035.14225.4
Syed, O. A., Petranker, R., Nestor, S. M., Husain, M. I., Lipsman, N., Alam, F., Giacobbe, P., Lake, S., & Lucas, P. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2730550
Feeling safe: an empirical-ethical analysis of vulnerability in (es)ketamine treatment
Kind, A., Görke, J., Smirr, H., Ni, C., Yan, K., & Repantis, D. (2026) · BMC Medical Ethics · doi:10.1186/s12910-026-01637-7
“In 2019, the FDA and EMA approved esket-amine nasal spray for treatment-resistant depression; intravenous (IV) ketamine infusions, meanwhile, remain a widely used off-label treatment for the same indication and for various other psychiatric disorders [1–4].”
Alves, G. S., Santos, H. M. M. D., Damasceno, S. D., MACIEL, L. M. S., da Silva, O. A. F. S., Fe, C. S. D. M., de Santana, J. G., de Freitas, M. B. L., Carvalho, A. F., & Monteiro, D. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1963841
“Our results highlight the need for standardization, transparency, and monitoring of off-label SC and IV esketamine across Brazilian services (33).”
Ketamine after the hype: What are we actually treating?
Movahed, P. (2026) · Australasian Psychiatry · doi:10.1177/10398562261508726
Metadata
- Authors
- Wilkinson, S. T., Toprak, M., Turner, M. S., Levine, S. P., Katz, R. B., & Sanacora, G.
- Affiliations
- Yale University (US)
- Venue
- American Journal of Psychiatry
- Published
- 2017-07-01
- Volume
- 174
- Issue
- 7
- Pages
- 695-696
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC5549850
- OpenAlex
- W2731109846
- Cited by
- 125
- References
- 5
- Citations by year
- 2026: 12 · 2025: 11 · 2024: 15 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 10 · 2019: 18 · 2018: 18 · 2017: 3
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK6 RX002458)
- National Institutes of Health (UL1TR001863)
- National Institute of Mental Health (T32MH062994, L30 MH111000)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- ketamine, off-label drug use, mental illness, treatment-resistant depression
- MeSH terms
- Antidepressive Agents, Bipolar Disorder, Depressive Disorder, Humans, Ketamine, Stress Disorders, Post-Traumatic, Treatment Outcome, Antimanic Agents, Health Care Surveys, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.